Canadian Nuclear Laboratories’ Post

2024 Highlight - #CNL successfully demonstrated the full production cycle for the promising radioisotope #Actinium-225. This work includes the successful target design, fabrication, irradiation, processing, and final shipment of the product. Overall, the project team has demonstrated that the #technology platform is sound, the logistics are manageable, and that the Actinium-225 production goals are achievable. This increased supply will enable more #research and trials, helping bring this breakthrough cancer fighting #radioisotope further towards broad #patient use. #science #medicine

Yesterday at #ASCO24, Shasqi’s Founder & CEO, José M. Mejía Oneto presented data from our Phase 2a study in patients with soft tissue sarcoma. This trial represents the first successful dose escalation of doxorubicin beyond 4x in a clinical trial: using our CAPAC technology to activate chemotherapy at the tumor, we were able to dose 12x the standard dose of doxorubicin per cycle without any DLTs, and with mild and manageable myelosuppression. Thanks to our PIs: Nam Bui, Vineet Kwatra, Christopher W. Ryan, MD, Erlinda Maria Gordon MD and Sant Chawla and to the patients and their families for participating in this study. Read the full poster here👇 https://bit.ly/3VpEuHR

🔬 Insights from ASCO 2024! Prof Mariana Brandao from Institut Jules Bordet presents the latest ctDNA analysis from the ADAURA trial on adjuvant osimertinib in resected stage I-III NSCLC. The study suggests that ctDNA monitoring could help tailor treatment duration, potentially reducing toxicity and improving patient quality of life. Discover the implications for clinical practice. Discover these updates.👇 For all ASCO 2024 videos, find the link in the comments! #MediMix #ASCO2024 #LungCancer #OncologyInnovation #ADAURATrial #ctDNA

Take your RNA-seq experiments to the next level with insights from Roche! Compare library preparation kits and optimize your tumor profiling workflow for maximum impact. Learn more >>> https://hubs.ly/Q02v0kxG0

A defining feature of #MIVO platform is its optical transparency, which opens new frontiers for non-invasive investigations and in-depth analysis of cellular interactions in complex biological systems. To further support researchers, we have developed a dedicated support system for hosting MIVO platforms, ensuring compatibility with the most common microscopy techniques. This tailored solution enables seamless integration into research workflows, allowing for monitoring of biological processes directly within the MIVO chambers, providing valuable insights across a wide range of applications, including cancer research and drug development.

We're 1 month away from the 𝟲𝘁𝗵 𝗠𝗮𝗰𝗿𝗼𝗽𝗵𝗮𝗴𝗲-𝗗𝗶𝗿𝗲𝗰𝘁𝗲𝗱 𝗧𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 𝗦𝘂𝗺𝗺𝗶𝘁—a key event for C-Level Executives, VPs, and Directors focused on macrophage therapies. 𝗗𝗼𝘄𝗻𝗹𝗼𝗮𝗱 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗲𝘃𝗲𝗻𝘁 𝗴𝘂𝗶𝗱𝗲 𝗵𝗲𝗿𝗲 - https://ter.li/insgj2 This is your opportunity to learn about: 💡𝗦𝗲𝗰𝘂𝗿𝗶𝗻𝗴 𝘃𝗶𝘁𝗮𝗹 𝗳𝘂𝗻𝗱𝗶𝗻𝗴 by uncovering exactly what partners are looking for. 💡𝗘𝘅𝗽𝗮𝗻𝗱𝗶𝗻𝗴 𝘆𝗼𝘂𝗿 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗰 𝗿𝗼𝗮𝗱𝗺𝗮𝗽 with expert insights on the latest macrophage therapies across multiple indications. 💡𝗦𝘁𝗮𝘆𝗶𝗻𝗴 𝗮𝗵𝗲𝗮𝗱 𝗼𝗳 𝘁𝗵𝗲 𝗰𝘂𝗿𝘃𝗲 with groundbreaking advancements in CAR-M for solid tumors.   Our FINAL earlybird savings expire next Friday. 𝗘𝘅𝗽𝗹𝗼𝗿𝗲 𝗱𝗶𝘀𝗰𝗼𝘂𝗻𝘁𝘀 𝗶𝗻 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗮𝗴𝗲𝗻𝗱𝗮 - https://ter.li/insgj2   Will you be missing out?   #𝗠𝗮𝗰𝗿𝗼𝗽𝗵𝗮𝗴𝗲𝗗𝗶𝗿𝗲𝗰𝘁𝗲𝗱𝗧𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀𝗦𝘂𝗺𝗺𝗶𝘁

Interested in learning more about Ori Biotech's new #IRO manufacturing platform? More detail and data showcasing our ability to automate better biology in the release below. #CGT #CellTherapy #Biotechnology

As of last week's ISCT conference, the cat is finally out of the bag on Ori's novel technology and superior biological performance. As someone who has been in the middle of this maturing industry for over 15 years, I am convinced that this is the step change in manufacturing that the industry so urgently needs. Check it out via our website and form your own opinion ..... and get yourself lined up for a demo!

Happy to share recent results on a new proximity #biosensor assay for the biophysical screening of bifunctional molecules: https://lnkd.in/eFUumGZc Inducing proximity between proteins-of-interest is a key mechanism in novel pharmacological modalities like #TargetedProteinDegradation. Many chemical inducers of proximity are currently under investigation, including bifunctional small and large molecules such as #PROTACs, #MolecularGlues, RIPTACs, TCIPs, or PROTABs. The #kinetics of formation and decay of ternary complexes (on- and off-rates) play an important role in the selection of candidates for further #DrugDevelopment. A major current limitation is the lack of efficient methods for the screening of ternary binders in high throughput. Our method enables the direct interrogation of ternary interactions, making the discovery of bifunctional molecules more straightforward. Many thanks to Alessio Ciulli at the Centre for Targeted Protein Degradation and Stefan Geschwindner at AstraZeneca for the fantastic collaboration and their guidance. Special thanks to Charlotte Crowe (Uni Dundee), Goran Dahl (AZ), and our own Irene Ponzo and Alice Soldà at Dynamic Biosensors for their amazing work. We hope this will become a useful tool in the fight against #cancer.

Good morning San Diego! Day two of #AACR24 … an overwhelming amount of interesting science, in the plenaries, posters and vendor booths. Some hot takes, which might be biased through my eyes… This year the buzziest categories of drugs are ADCs and KRAS agents. In my opinion, both are categories that will benefit dramatically from next generation Biomarkers to guide patient stratification, trial design and ultimately treatment decisions. If you agree, or, if you disagree, check out the Genialis poster tomorrow, presenting Genialis krasID, a first in class machine learning-driven predictive biomarker for response and benefit to KRAS inhibitors. www.genialis.com/krasID